Recent Korean Biotech Licensing Out Deals
Edited by Jin Medical Science Service
Embedded Files
IMB-101 is a bispecific antibody, which targets both the autoimmune disease antibody OX40L and tumor necrosis factor alpha (TNF-α ), and IMB-102 is a monospecific antibody, which targets OX40L only.
Indications: Autoimmune diseases
Date: Aug-14-2024
Licensing Stage: Phase 1 NCT06181786
Korean Licensor: IMBiologics
Chinese Licensee: Huadong Medicine
Territory: 37 Asian countries, excluding Japan and Korea
Upfront Payment: 6,000,000 USD
Milestone Payment: 2,000,000 USD
Royalty: Two digits
AR1001 is a potent PDE5 inhibitor being developed as a multi-modality oral treatment that can simultaneously target the complex and diverse pathology of Alzheimer's disease.
Indications: Alzheimer's disease
Date: Mar-24-2024
Licensing Stage: Phase 3 NCT05531526
Korean Licensor: AriBio
Chinese Licensee: NeuCo United
Territory: China
Upfront Payment: 90,000,000 USD
Milestone Payment + Royalty: 770,000,000 USD
Zastaprazan (JAQBO®) is a next-generation potassium-competitive acid blocker. In April 2024, zastaprazan received approval in S. Korea for the treatment of erosive gastroesophageal reflux disease (GERD).
Indications: GERD
Date: Mar-10-2023
Licensing Stage: Phase 3 NCT05443984
Korean Licensor: Onconic Therapeutics
Chinese Licensee: Livzon
Territory: Greater China
Upfront Payment: 15,000,000 USD
Milestone Payment + Royalty: Maximum 112,500,000 USD
Risuteganib is a novel anti-integrin peptide that targets integrin-mediated cellular interactions involved in angiogenesis and inflammation, key pathological mechanisms of dry AMD.
Indications: Dry age-related macular degeneration (AMD)
Date: Dec-31-2021
Licensing Stage: Phase 2 NCT03626636
Korean Licensor: Hanmi Pharmaxeutical
Chinese Licensee: AffaMed Therapeutics
Territory: Great China
Upfront Payment: 6,000,000 USD
Milestone Payment: 139,000,000 USD
Royalty: Not disclosed
Batoclimab is a fully humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn). It represents a promising therapeutic option for IgG-mediated autoimmune diseases by reducing circulating IgG levels.
Tanfanercept is an anti-TNFα fusion protein designed to provide enhanced tissue penetration.
Indications: Autoimmune (HL161) and dry eye (HL036) diseases
Date: Sep-12-2017
Licensing Stage: Preclinical (HL161) and Phase I (HL036)
Korean Licensor: HanAll Biopharma
Chinese Licensee: Harbour BioMed
Territory: Greater China
Upfront Payment: 4,000,000 USD
Milestone Payment + Royalty: 77,000,000 USD
Page updated
Google Sites
Report abuse